Candicidin

CHEMBL6067990 Phase 4 Disetujui Unknown
Half-Life
Bioavailability
Protein Binding
Molecular Weight
1109.3 g/mol
LogP
1.8
Phase
4

An antifungal antibiotic derived from Streptomyces bacteria that was used historically to treat vaginal candidiasis. It works by binding to ergosterol in fungal cell membranes, causing membrane disruption and cell death. It has largely been replaced by azole antifungals in clinical practice.

Berat Molekul

1109,3000 g/mol

LogP

1,80

TPSA

364,00 Ų

Lipinski RO5

Gagal

Area Terapeutik

Mekanisme Kerja

Inhibits the fungal cytochrome P450 enzyme lanosterol 14-alpha-demethylase, blocking ergosterol synthesis essential for fungal cell membrane integrity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Inhibits the fungal cytochrome P450 enzyme lanosterol 14-alpha-demethylase, blocking ergosterol synthesis essential for fungal cell membrane integrity.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@@H]1[C@H]([C@@H]([C@@H](C(O1)OC\2CC(C(C(CC(=O)CC(CC(CC(CC(=O)CCCC(=O)CC(=O)OC(C(/C=C/C=C/C=C/C=C/C=C/C=C/C=C2)C)C(C)CC(C)C(CC(=O)C3=CC=C(C=C3)N)O)O)O)O)O)C(=O)O)O)O)N)O

InChI

InChI=1S/C59H84N2O18/c1-35-18-15-13-11-9-7-5-6-8-10-12-14-16-21-47(78-59-56(74)54(61)55(73)38(4)77-59)33-51(71)53(58(75)76)50(70)31-46(67)30-45(66)29-44(65)28-43(64)27-41(62)19-17-20-42(63)32-52(72)79-57(35)37(3)26-36(2)48(68)34-49(69)39-22-24-40(60)25-23-39/h5-16,18,21-25,35-38,43-45,47-48,50-51,53-57,59,64-66,68,70-71,73-74H,17,19-20,26-34,60-61H2,1-4H3,(H,75,76)/b6-5+,9-7+,10-8+,13-11+,14-12+,18-15+,21-16+/t35?,36?,37?,38-,43?,44?,45?,47?,48?,50?,51?,53?,54+,55-,56+,57?,59?/m1/s1

Molecular Formula

C59H84N2O18

HBD / HBA

11 / 20

Ikatan yang Dapat Dirotasi

10

Atom Berat

79

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

An antifungal antibiotic derived from Streptomyces bacteria that was used historically to treat vaginal candidiasis. It works by binding to ergosterol in fungal cell membranes, causing membrane disruption and cell death. It has largely been replaced by azole antifungals in clinical practice.

Inhibits the fungal cytochrome P450 enzyme lanosterol 14-alpha-demethylase, blocking ergosterol synthesis essential for fungal cell membrane integrity.

Yes, Candicidin is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6067990. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 10079874. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.